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Abstract. A new simple, sensitive and LC-MS/MS method for quantification of spironolactone and its me-
tabolite, canrenone, in human plasma is proposed. The analytes were analysed on a C18 column at 48 ºC, 
by using a mobile phase of 58 % methanol, 42 % 10 mmol dm−3 ammonim acetate in water and a flow 
rate of 1 mL/min. The detection of both analytes in plasma was performed as follows: ESI+, EIC (m/z 
169;187;283;305) from m/z 341, after protein precipitation with methanol. Calibration curves were gener-
ated over the ranges 2.77–184.50 ng/mL for spironolactone and 2.69–179.20 ng/mL for canrenone by us-
ing a weighted (1/y) linear regression. The absolute values of within- and between-run precision and accu-
racy for both analytes ranged between 3.1 and 13.9 %, and the mean recovery was 99.7 %. The analytes 
demonstrated good stability in various conditions. The validated method has been applied to a bioequiva-
lence study of 50 mg spironolactone tablets on healthy volunteers. (doi: 10.5562/cca1761) 
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INTRODUCTION 
Spironolactone (SPR) is a mineralocorticoid (aldoste-
rone) receptor antagonist (aldosterone antagonist) and a 
potassium-sparing diuretic.1 It is mainly metabolised in 
humans to 7-thiomethylspirolactone and canrenone 
(CNR) (Figure 1). SPR is indicated for the treatment of 
congestive heart failure, oedema and ascites in cirrhosis 
and primary hyperaldosteronism. Due to its antiandro-
gen effect, it can also be used to treat hirsutism, and is a 
common component in hormone therapy for male-to-
female transsexual and transgender people. It is also 
used for treating hair loss and acne in women, and can 
be used as a topical medication for treatment of male 
baldness. 
Numerous HPLC methods have been developed 
for SPR and its metabolites determination in plasma or 
serum,2 and only a few used liquid chromatography 
coupled with mass spectrometry as analytical tool for 
this kind of determination.3,4 However, an important 
number of papers in which LC-MS determination of 
SPR from urine (doping agents screening) and milk are 
described.5–12 
In the present study, we attempted to develop a 
fast and sensitive LC-MS/MS method able to quantify 
SPR and CNR in human plasma after oral administra-
tion of a single dose of 100 mg (2 × 50 mg) SPR by 
applying a simple protein precipitation, with a very 
short run-time. Finally, the developed and verified me-
thod was used for bioequivalence investigation of two 
oral medicinal products containing 50 mg SPR. 
Figure 1. Chemical structures of spironolactone (a) and
canrenone (b). 
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EXPERIMENTAL 
Reagents 
Spironolactone and canrenone were European Pharma-
copoeia certified reference standards. Methanol and 
ammonium acetate were Merck products (Merck KgaA, 
Darmstadt, Germany). Ultrapure, deionised water was 
produced by a Millipore (Millipore SA, Molsheim, 
France) water system. The human blank plasma was 
supplied from healthy volunteers. 
 
Standard Solutions 
Two stock solutions of SPR and CNR with concentra-
tion of 1.3 mg/mL and 0.45 mg/mL, respectively, were 
prepared by dissolving appropriate quantities of refer-
ence substances (weighed on an analytical balance Ana-
lytical Plus from Ohaus, USA) in 10 mL methanol. Two 
working solutions were then obtained by diluting specif-
ic volumes of each stock solution with methanol. Eight 
plasma calibration standard with the following concen-
tration domains were obtained for each analyte: 2.8–
184.5 ng/mL SPR and 2.7–179.2 ng/mL CNR. Accura-
cy and precision of the method were verified using 
quality control (QC) plasma standards with three levels 
of concentration: QCA – 9.23 ng/mL SPR, 8.96 ng/mL 
CNR; QCB – 27.68 ng/mL SPR and 26.88 ng/mL CNR; 
QCC –73.81 ng/mL SPR and 71.68 ng/mL CNR. The 
same types of quality control samples (QC) were used 
during clinical samples analysis in order to further eva-
luate the accuracy of the method. 
 
Chromatographic and Mass Spectrometry Systems 
and Conditions 
The HPLC system was an 1100 series model (Agilent 
Technologies, USA) consisting of a binary pump, an in-
line degasser, an autosampler, a column thermostat, and 
an Ion Trap SL mass spectrometer detector (Brucker 
Daltonics GmbH, Germany). Chromatograms were 
processed using QuantAnalysis software. The detection 
of the analytes: ESI+, EIC (m/z 169, 187; 283; 305) 
from m/z 341. Other detector parameters were: dry tem-
perature 225 C, nebulizer 60 psi, dry gas – nitrogen at 
12 L/min, ion charge control ON, accumulation time 
400 ms. The electrospray capillary was set to 4000 V 
for spironolactone and 2000 V for canrenone. The 
chromatographic separation was performed at 48 C on 
a Zorbax SB-C18 100 × 3.0 mm, 3.5 m (Agilent Tech-
nologies), protected by an in-line filter. 
 
Mobile Phase 
The mobile phase consisted of a mixture of 58 % 
methanol and 42 % 10 mmol dm−3 ammonim acetate in 
water, each component being degassed, before elution, 
for 10 minutes in a T700H (Elma Transsonic, Singen, 
Germany) ultrasonic bath. The pump delivered the mo-
bile phase at 1 mL/min. 
 
Sample Preparation 
Standard and test plasma samples were prepared as 
follows in order to be chromatographically analyzed. 
In an Eppendorf tube, to 0.2 ml plasma, a volume of 
0.5 ml methanol was added. The tube was vortex-
mixed for 10 seconds via Genie 2 vortex (Scientific 
Industries, USA) and then centrifuged for 6 minutes at 
4000 rpm (204 Sigma centrifuge, Osterode am Harz, 
Germany). The supernatant was transferred in an auto-
sampler vial and 10 L were injected into the chroma-
tographic system. 
 
Analytical Performances of the Method 
Specificity of the method was investigated by analysing 
blank plasma samples of six individual healthy volun-
teers for interference of endogenous compounds with 
the analytes. Investigation of the selectivity was carried 
out together with the calibration curve assay. In order to 
prove selectivity, chromatograms of the blank plasma 
extracts must not exhibit significant peak at the reten-
tion time of the examined peaks. The result was consid-
ered acceptable if the peak height of the endogenous 
compound at the retention time of analyte was not more 
than 20 % of the mean peak height obtained for the 
lowest level calibration solution. 
The matrix effect was also investigated. The ion 
suppression was calculated as relative difference be-
tween the analytical response for a mixture of SPR and 
CNR at quantification limit injected directly in mobile 
phase and the response of analytes added to preextracted 
blank plasma samples.13 
The concentration of analytes in plasma samples 
was determined automatically by the instrument data 
system using the external standard method. Linearity 
verification was performed using singlicate calibration 
standards on five different days. The calibration curve 
model was determined by the least squares analysis. The 
applied calibration model was a linear one: y = ax + b, 
weight 1/y, where y – peak area and x – concentration, 
in ng/mL. Distribution of the residuals (% difference of 
the back-calculated concentration from the nominal 
concentration) was investigated. The calibration model 
was accepted, if the residuals were within 20 % at the 
lower limit of quantification (LLOQ) and within 15 % 
at all other calibration levels and at least six out of eight 
calibration standards met this criterion, including high-
est and lowest calibration levels. 
The LLOQ was investigated at the level of the 
lowest calibration standard, when the accuracy and 
precision have to be less than 20 %. 
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The within- and between-run precision (expressed 
as coefficient of variation, CV%) and accuracy (ex-
pressed as relative difference between obtained and 
theoretical concentration, Bias%) of the assay procedure 
were determined by analysis on the same day of five 
different samples at each of the lower (QCA), medium 
(QCB), and higher (QCC) levels of the considered con-
centration range and one different sample of each on 
five different days, respectively. 
The relative recoveries at each of the previously 
three levels of concentration and LLOQ were measured 
by comparing the response of the treated plasma stan-
dards with the response of standards in solution with the 
same concentration of analytes as the prepared plasma 
sample. 
The stability of the analytes in human plasma was 
investigated in four ways, in order to characterize each 
operation during the process of bioequivalence studies: 
room temperature stability (RTS), post-preparative 
stability (PPS) in autosampler, freeze-thaw stability 
(FTS) and long-term stability (LTS) below −25 oC. For 
all stability studies, plasma standards at each of the 
lower (QCA) and higher (QCC) QC levels were used. 
Four pairs were prepared and let at room temperature 
for four hours, then processed and analyzed. Eight pairs 
were prepared and processed, four pairs were imme-
diately analyzed and the other four stored in the HPLC 
autosampler (20 C) (PPS study). The stored samples 
were injected after 3.5 hours, the expected longest sto-
rage times of the samples in autosampler before injec-
tion. For the freeze-thaw stability (FTS), four aliquots at 
the same low and high concentrations were prepared. 
These samples were subjected to three cycles of freeze-
thaw operations in three consecutive days. After the 
third cycle the samples were analyzed against calibra-
tion curve of the day. The mean concentration calcu-
lated for the samples subjected to the cycles and the 
nominal ones were compared. For long-term stability 
(LTS), in the first validation day, four pairs were pre-
pared and analyzed and concentration values were de-
termined against calibration curve of the day. Other four 
sets were stored in freezer below −25 °C and analyzed 
together with calibration samples on four different occa-
sions during three months. The values were calculated 
against calibration curve of the day and the mean values 
for the stored samples and nominal concentrations were 
compared. The requirement for stable analytes was that 
the difference between mean concentrations of the 
tested samples in various conditions and nominal con-
centrations had to be in ±15 % range. 
The ability to dilute samples with concentrations 
above the upper limit of quantification was also investi-
gated. Plasma standards (n = 5) with 922.6 ng/mL SPR 
and 896 ng/mL CNR were ten times diluted with plasma 
then processed and analyzed. The mean concentration 
found was compared with the nominal value. The accu-
racy and precision had to be within 15% range. 
 
Clinical Application 
The validated method was applied in a bioequivalence 
study of two dosage forms – tablets containing 50 mg 
SPR, after oral administration of 100 mg SPR. Seven-
teen collecting times within 72 hours were used. The 
accuracy of the validated method was monitored to 
ensure that it continued to perform satisfactorily during 
analysis of volunteer samples. To achieve this objective, 
a number of QC samples prepared in duplicate at three 
concentration levels were analyzed in each assay run 
and the results compared with the corresponding cali-
bration curve. The runs were accepted if at least four out 
of six QC were within ±15 %. 
 
RESULTS AND DISCUSSION 
The recorded mass spectrum of canrenone is presented 
in Figure 2. 
During electrospray evaporation and ionization 
process, spironolactone readily loses the 7α-acetylthio 
group being transformed to canrenone, so it was quanti-
fied in that form. However, the spironolactone signal 
can be easy distinguished from the canrenone signal by 
different retention times of the two compounds. 
A blank, a plasma standard sample at quantifica-
tion limit and a clinical sample are shown in Figure 3. 
No significant interferences at the retention time of SPR 
(2.9 min) and CNR (3.8 min) were observed in different 
plasma blank samples chromatograms due to the speci-
ficity of selected signals. 
However, during the method development and us-
ing a capillary potential of 4000 V, an interfering peak 
with retention time of 3.5 min was observed near ca-
nrenone, making its quantification difficult (Figure 4). 
The mass spectrum of the interfering peak was found to 
Figure 2. MS spectra of canrenone: upper: full scan spectra in
mobile phase, middle: isolation of m/z 341, lower: fragmenta-
tion spectra (MS/MS). 
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be identical to that of canrenone, so it may be another 
metabolite of spironolactone which, as spironolactone, 
is easily transformed in canrenone during ionization 
and solvent evaporation (cross-talking). However, by 
lowering the capillary voltage from 4000 V to 2000 V, 
that interference became negligible, probably due to 
milder ionization conditions in electrospray ion source 
at lower voltages which minimize the cross-talking 
process. This kind of interference due to sample struc-
turally-related compounds was already reported in 
literature.14 
No significant matrix effects – ion suppression were 
observed for SPR or CNR when comparing the analytical 
signal obtained for analytes dissolved in mobile phase or 
in blank plasma sample extracts. The analyte carryover 
was verified using a blank injection made right after an 
injection of the most elevated level of concentration from 
calibration curve. No interference was observed at the 
retention times of the analytes as a result of carryover. 
The applied calibration curve model proved to corre-
late adequately with the experimental data over the con-
centration range 2.77–184.50 ng/mL for SPR and 2.69–
179.20 ng/mL for CNR (correlation coefficient greater 
than 0.993). The mean calibration curves (N = 8 calibra-
tion points, n = 5 determinations for each calibration 
point) were: for SPR y = 2922 (±352) x – 1121 (±779), for 
CNR y = 3883 (±229) x
 – 1947 (±505). The residuals of 
the calibration points had no tendency of variation with 
concentration and at least six out of eight were within ±15 
%, including LLOQ and upper limit of quantification. 
The method had within- and between-run accuracy 
and precision (Tables 1 and 2), in agreement to interna-
tional regulations regarding bioanalytical methods vali-
dation.15,16 The lower limits of quantification were es-
tablished at 2.77 ng/mL for SPR and 2.69 ng/mL for 
Figure 3. Chromatograms of blank plasma (upper image),
plasma spiked with SPR (1) and CNR (2) at LLOQ (middle)
and a clinical sample obtained at 2 hours after oral administra-
tion of 100 mg SPR to a healthy volunteer; found concentra-
tions: SPR – 16.6 ng/ml, CNR – 63.3 ng/ml (lower image). 
Figure 4. Effect of electrospray capillary voltage on method
selectivity for canrenone (RT 3.7 min): upper image: 4000 V,
middle: 3000 V, lower: 2000 V. The interfering peak with RT
3.5 min is marked with an arrow. 
Table 1. Within-run precision, accuracy and recovery for SPR and CNR (n = 5) 
cnominal / ng ml
−1 
Mean cfound / ng ml
−1 (±SD) 
Recovery / % (SD) 
CV / % Bias / % 
























10.6 3.7 −3.5 −7.1 
L. Vlase et al., LCMS Determination of Spironolactone and Canrenone 365 
Croat. Chem. Acta 84 (2011) 361. 
CNR, respectively, with accuracy and precision less 
than 20 % (Tables 1 and 2). 
The recovery was consistent and reproducible 
(Tables 1 and 2). 
The analytes proved their stability under various 
conditions (Table 3), the Bias% of found concentration 
being less than 15 %, the maximum accepted value for 
method’s accuracy. 
The sample dilution could be made with accuracy 
within  9.5 % range and precision less than 11.2 %, for 
both analytes within- and between-assay. 
The validated method was verified during analysis 
of clinical samples from a bioequivalence study (24 
healthy volunteers) of two medicines containing 50 mg 
SPR. Figure 5 shows the mean concentration profiles of 
SPR and CNR, after oral administration of 100 mg SPR. 
Table 2. Between-run precision, accuracy and recovery for SPR and CNR (n = 5) 
cnominal / ng ml
−1 
Mean cfound / ng ml
−1 (±SD) 
Recovery / % (SD) 
CV / % Bias / % 


















13.9 7.6 −9.8 −0.7 




11.5 9.5 −8.5 −9.9 
 
 
Table 3. Results of the stability studies (n = 4) 
 
RTS PPS FTS LTS 
cnominal / ng ml
−1 
SPR / CNR 
9.23/8.96 73.81/71.68 9.23/8.96 73.81/71.68 9.23/8.96 73.81/71.68 9.23/8.96 73.81/71.68 
Bias / %, SPR −8.9 −10.2 −4.3 −13.2 −8.8 −11.3 −10.7 −9.3 
Bias / %, CNR −9.8 −5.9 −11 −10.5 −11.6 −7.8 −3.2 −7.9 
*RTS – room temperature stability (four hours), PPS – post-preparative stability (20 C, 3.5 hours), FTS – freeze – thaw stability 
(3 freeze-thaw cycles), LTS – long term stability (−28 C, three months). 
Figure 5. Mean concentration profiles of SPR () and CNR () in plasma after oral administration of 100 mg spironolactone
(n = 24 volunteers). 
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The method continued to perform in terms of ac-
curacy during the analysis of clinical samples, in each 
analytical run not more than two out of six QC samples 
being outside of ±15 % nominal value, but not all two at 
the same concentration. 
There are only few articles about SPR and CNR 
determination in human plasma by LC-MS/MS. The 
proposed method has real advantages in terms of sensi-
tivity and high-throughput features. The necessary 
plasma volume allows the analysis of paediatric 
plasma samples, too. The analytes could be determined 
with accuracy and precision for quantities starting 
from 7.8 pg injected into column, in comparison with 
another method in which a run time of 13 minutes and 
time and material consuming sample preparation like 
liquid-liquid extraction were applied in order to deter-
min quantities above 200 pg injected.3 Another advan-
tage of the actual method is the high sample through-
put due to the sample preparation by protein precipita-
tion combined with a short run-time of analysis, in 
comparison with a recent article in which protein pre-
cipitation is used, but large injection volume (corre-
sponding to 133 pg of analytes injected) and long run-




The proposed method provides accuracy and precision 
for quantitative determination of spironolactone and 
canrenone in human plasma after oral administration of 
100 mg spironolactone. The simple sample preparation 
by protein precipitation, the relatively short run time 
and the selected signals for monitoring allowed a specif-
ic and efficient analysis of plasma samples, making the 
method more productive and thus more cost effective. 
As far as we are aware, this is the first high throughput 
LC-MS/MS method for spironolactone and canrenone 
quantification in human plasma after protein precipita-
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